Physician profile
Gil A Epstein
NPI 1679575351
$4,607.10
in general payments reported to CMS, 2019-2025
22 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $345 · 2021: $1,072 · 2022: $1,391 · 2023: $514 · 2024: $327 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.28 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $1,925.61 | 2019-2022 | |
| Horizon Therapeutics Plc | $904.05 | 2019-2023 | Tepezza |
| Abbvie INC. | $453.02 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $233.76 | 2019 | |
| Bausch & Lomb Americas INC. | $142.55 | 2022-2024 | Vyzulta |
| Biotissue Holdings INC. | $139.68 | 2019-2022 | |
| Genentech USA, INC. | $138.05 | 2021 | |
| Alcon Vision LLC | $122.47 | 2023 | Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $96.32 | 2022-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $87.70 | 2025 | Acthar |
| Amgen INC. | $75.32 | 2024-2025 | Tepezza |
| Merz Pharmaceuticals, LLC | $42.57 | 2023 | Xeomin |
| Dompe US, INC. | $42.13 | 2021 | |
| Sun Pharmaceutical Industries INC. | $41.48 | 2019-2022 | |
| Ocular Therapeutix, INC. | $32.77 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $30.35 | 2019-2021 | |
| Allergan, INC. | $21.18 | 2022 | |
| Coherus Oncology, INC. | $17.94 | 2022 | |
| Harrow Eye, LLC | $15.84 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $15.06 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $14.85 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$68,264.29 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gil Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.